https://doi.org/10.48047/AFJBS.6.2.2024.4409-4414

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Neonatal Respiratory Distress: Current Insights and Future Directions in Diagnosis and Management

Sammer Alsayed Mohamed Ahmed[1], Wafaa Fathy Alsaeed[1], Ehab Abdelmonem Elbanah[1], Sameh Saber Bayoumi[2], Sahbaa Fehr Mohamed [1]

1 Pediatrics Department, Faculty of Medicine - Zagazig University, Egypt

2 Radiology Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Sammer Alsayed Mohamed Ahmed

Email: Sammeralsayed10@gmail.com

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 5 August 2024

Accepted: 15 August 2024

Published: 15 August 2024

doi:10.48047/AFJBS.6.2.2024.4409-4414

Abstract: Background: Neonatal respiratory distress remains a significant clinical challenge, contributing to substantial neonatal morbidity and mortality worldwide. This review explores the multifactorial etiology, pathophysiology, diagnostic approaches, and management strategies for neonatal respiratory distress. Common causes such as respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), meconium aspiration syndrome (MAS), pneumonia, and congenital anomalies are discussed in detail. The article highlights advances in diagnostic modalities, including bedside lung ultrasound and blood gas analysis, which have improved early detection and differentiation of underlying causes. Furthermore, evidence-based therapeutic interventions, such as surfactant replacement therapy, non-invasive ventilation strategies, and the role of antenatal corticosteroids, are reviewed. Emphasis is also placed on the importance of a multidisciplinary team approach in optimizing outcomes for neonates with respiratory distress. Future directions, including emerging therapies and ongoing research, are explored to address existing gaps in knowledge. This review aims to provide clinicians and healthcare professionals with a comprehensive understanding of neonatal respiratory distress to enhance early recognition, effective management, and improved neonatal outcomes.

Keywords: *neonatal, respiratory distress*

Introduction

Neonatal respiratory distress (NRD) remains one of the most common and critical conditions in newborns, contributing significantly to neonatal morbidity and mortality worldwide [1]. It encompasses a spectrum of respiratory disorders, including respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), meconium aspiration syndrome (MAS), pneumonia, and congenital malformations. Early recognition, accurate diagnosis, and timely intervention are pivotal in improving neonatal outcomes [2]. Despite significant advances in neonatal care, respiratory distress continues to pose a significant challenge, especially in resource-limited settings. Understanding the underlying mechanisms, diagnostic modalities, and therapeutic strategies is essential for optimizing outcomes and preventing long-term complications. This review aims to provide an in-depth analysis of NRD, exploring the latest evidence-based practices and highlighting areas requiring further research.

Pathophysiology of Neonatal Respiratory Distress The pathophysiology of NRD is multifactorial, with causes varying depending on gestational age, underlying conditions, and perinatal factors [3].

Respiratory Distress Syndrome (RDS): RDS primarily affects preterm neonates due to surfactant deficiency. Surfactant, a complex mixture of phospholipids and proteins, reduces alveolar surface tension and prevents alveolar collapse during expiration [4]. Without adequate surfactant, the lungs become stiff, leading to poor lung compliance, atelectasis, and impaired gas exchange. Preterm neonates also have immature type II pneumocytes, further exacerbating surfactant deficiency. The resulting hypoxemia and hypercapnia can cause severe respiratory acidosis and multiple organ dysfunction. Additionally, RDS is exacerbated by factors such as maternal diabetes, perinatal asphyxia, and genetic predisposition. Timely administration of surfactant therapy and antenatal corticosteroids has significantly reduced mortality and improved outcomes in affected neonates.

Transient Tachypnea of the Newborn (TTN): TTN occurs when fetal lung fluid clearance is delayed or incomplete, leading to respiratory distress shortly after birth [5]. Normally, fetal lung fluid is absorbed by the pulmonary lymphatics and blood vessels during labor and the initial breaths. In neonates delivered via cesarean section without labor, this process is disrupted, increasing the risk of TTN. Excess lung fluid interferes with effective gas exchange, causing tachypnea, mild hypoxemia, and increased work of breathing. TTN is often self-limiting and resolves within 48-72 hours, but supportive care with oxygen supplementation and non-invasive ventilation may be necessary in severe cases.

Meconium Aspiration Syndrome (MAS): MAS occurs when a neonate inhales meconium-stained amniotic fluid, usually in response to fetal hypoxia or distress [6]. Meconium can obstruct the airways, cause chemical pneumonitis, and inactivate surfactant. These combined effects lead to ventilation-perfusion mismatch, hypoxemia, and respiratory distress. Severe MAS may also cause persistent pulmonary hypertension, further complicating the clinical picture. Management includes suctioning at birth, surfactant therapy, and, in severe cases, extracorporeal membrane oxygenation (ECMO).

Pneumonia and Sepsis: Neonatal pneumonia can result from intrauterine infections, perinatal exposure, or postnatal infections. Infectious agents like Group B Streptococcus, E. coli, and respiratory viruses can cause significant inflammation and alveolar damage, impairing oxygenation [7]. Sepsis often coexists with pneumonia, leading to systemic inflammatory responses, poor perfusion, and multi-organ involvement. Early identification and initiation of appropriate antibiotic therapy are critical for improving outcomes.

Pulmonary Hypertension: Persistent pulmonary hypertension of the newborn (PPHN) results from the failure of pulmonary vascular resistance to decrease after birth [8]. This condition causes right-to-left shunting of blood through the ductus arteriosus and foramen ovale, leading to severe hypoxemia. PPHN is commonly associated with MAS, RDS, and congenital heart defects. Management strategies include oxygen therapy, inhaled nitric oxide (iNO), and, in refractory cases, ECMO.

Clinical Assessment of Neonatal Respiratory Distress Clinical assessment remains the cornerstone for identifying NRD and determining its severity.

Apgar Score Assessment: The Apgar score is a rapid assessment tool performed immediately after birth to evaluate neonatal health [9]. It assesses five parameters: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. A low Apgar score indicates a higher risk of respiratory distress and the need for immediate intervention. Although not diagnostic, it provides an initial indication of the neonate's respiratory status. Low scores at one and five minutes are associated with increased risk of mortality and long-term neurodevelopmental delays.

Respiratory Signs: Clinical signs of respiratory distress include tachypnea (respiratory rate >60 breaths per minute), nasal flaring, intercostal and subcostal retractions, grunting, and cyanosis [10]. These signs suggest increased work of breathing and impaired oxygenation. Severe cases may present with apnea or bradycardia, necessitating immediate respiratory support. Continuous monitoring and early escalation of care are critical for preventing deterioration.

Silverman-Anderson Score: This scoring system evaluates the severity of respiratory distress based on five criteria: nasal flaring, chest movement, intercostal retractions, xiphoid retractions, and grunting [11]. A higher

score indicates more severe distress and the need for aggressive intervention. This tool is especially useful in monitoring disease progression. It is frequently used alongside other clinical and diagnostic tools for comprehensive assessment.

Blood Gas Analysis: Arterial blood gas (ABG) analysis provides crucial information about oxygenation, ventilation, and acid-base balance [12]. Hypoxemia, hypercapnia, and acidosis suggest significant respiratory compromise. ABG is often used to guide respiratory support strategies and monitor treatment response. Regular sampling may be required in critically ill neonates.

Imaging Studies: Chest X-rays and lung ultrasound are essential diagnostic tools for evaluating NRD [13]. Chest X-rays can identify patterns characteristic of RDS (ground-glass appearance), TTN (perihilar streaking), or MAS (patchy infiltrates). Lung ultrasound is gaining popularity due to its portability and accuracy in diagnosing various neonatal lung conditions. It allows repeated assessments without exposing the neonate to radiation.

Neonatal respiratory distress syndrome (RDS) remains a leading cause of morbidity and mortality among preterm infants. It is primarily caused by surfactant deficiency, leading to alveolar collapse, poor gas exchange, and respiratory failure [13]. The incidence of RDS is inversely related to gestational age, with infants born before 28 weeks being at the highest risk. Surfactant replacement therapy (SRT) has revolutionized the management of RDS, significantly reducing mortality and pulmonary complications in affected neonates [14]. Early recognition and prompt intervention are essential to prevent long-term sequelae such as bronchopulmonary dysplasia (BPD) and neurodevelopmental impairments [15].

The cornerstone of RDS management involves respiratory support and exogenous surfactant administration. Continuous positive airway pressure (CPAP) is often the initial respiratory support strategy, aiming to maintain functional residual capacity and reduce the work of breathing [16]. When CPAP alone is insufficient, mechanical ventilation may be initiated. However, mechanical ventilation carries the risk of ventilator-induced lung injury (VILI), which can exacerbate lung damage and lead to chronic lung disease [17]. To minimize these risks, gentle ventilation strategies and non-invasive ventilation techniques are increasingly preferred in neonatal intensive care units (NICUs) [18].

Exogenous surfactant therapy is a well-established intervention in RDS management. Natural surfactant preparations, derived from animal sources, have shown superior efficacy compared to synthetic surfactants [19]. Timing of surfactant administration is crucial; early administration within the first hour of life has been associated with better outcomes [20]. Prophylactic surfactant therapy is recommended for infants at extremely high risk of RDS, while rescue therapy is reserved for those showing clinical signs of respiratory distress [21]. Recent advances in surfactant administration techniques, such as the less invasive surfactant administration (LISA) method, have shown promising results in reducing the need for mechanical ventilation [22].

Antenatal corticosteroids play a pivotal role in preventing and managing RDS. Administration of corticosteroids to pregnant women at risk of preterm delivery accelerates fetal lung maturation and enhances endogenous surfactant production [23]. Studies have demonstrated a significant reduction in neonatal mortality, RDS incidence, and intraventricular hemorrhage following antenatal steroid administration [24]. Despite these benefits, optimal timing and dosing regimens remain an area of ongoing research [25].

Supportive care is a critical component of RDS management. Thermoregulation, fluid balance, nutritional support, and prevention of infection are essential to optimize neonatal outcomes [26]. Hypothermia can exacerbate respiratory distress, and therefore, maintaining a neutral thermal environment is paramount. Adequate fluid management prevents both dehydration and fluid overload, which can compromise respiratory function [27]. Parenteral nutrition is often necessary until enteral feeding can be safely established, supporting growth and recovery [28].

Non-invasive ventilation (NIV) has become a preferred strategy in the management of RDS due to its ability to provide respiratory support while minimizing the risks associated with invasive ventilation. Techniques such as CPAP, nasal intermittent positive pressure ventilation (NIPPV), and high-flow nasal cannula (HFNC) are commonly used in NICUs [29]. Studies have shown that early initiation of CPAP, even in the delivery room, can

reduce the need for intubation and mechanical ventilation [30]. NIV techniques require skilled personnel and appropriate equipment to ensure their effectiveness and safety [31].

Oxygen therapy is an integral part of RDS management, but it must be carefully monitored to avoid both hypoxia and hyperoxia. Excessive oxygen exposure can lead to oxidative stress and increase the risk of retinopathy of prematurity (ROP) and chronic lung disease [32]. Target oxygen saturation ranges have been established to balance the risks of hypoxemia and hyperoxemia, typically between 90-95% [33]. Pulse oximetry and blood gas analysis are essential tools for monitoring oxygenation and ventilation in neonates with RDS [34].

Surfactant protein deficiencies, either congenital or acquired, can contribute to severe RDS in some infants. Mutations in genes encoding surfactant proteins (e.g., SP-B and SP-C) can result in surfactant dysfunction and refractory respiratory failure [35]. Genetic testing and molecular diagnostics play a crucial role in identifying these rare causes of RDS. Infants with surfactant protein deficiencies often require prolonged respiratory support and may benefit from lung transplantation in severe cases [36].

Bronchopulmonary dysplasia (BPD) remains a significant long-term complication of severe RDS. It is characterized by impaired lung development and chronic respiratory symptoms persisting beyond 36 weeks postmenstrual age [37]. Strategies to prevent BPD include minimizing mechanical ventilation, using lung-protective strategies, optimizing nutrition, and preventing infections [38]. The role of postnatal corticosteroids in preventing BPD is still debated, with concerns regarding their potential adverse neurodevelopmental effects [39].

Advanced imaging techniques, such as lung ultrasound and magnetic resonance imaging (MRI), have improved the diagnosis and monitoring of RDS. Lung ultrasound is non-invasive, radiation-free, and provides real-time imaging, making it an attractive diagnostic tool in NICUs [40]. MRI offers detailed anatomical and functional imaging, helping to assess lung development and injury in preterm infants [41]. These imaging modalities complement traditional chest radiography in the comprehensive assessment of neonatal respiratory distress.

Further research into novel therapies for RDS is ongoing. Stem cell therapy, particularly mesenchymal stem cell transplantation, shows promise in promoting lung repair and regeneration [42]. Animal studies have demonstrated improved lung function and reduced inflammation following stem cell therapy. However, clinical trials are needed to confirm the safety and efficacy of these approaches in neonates [43]. Anti-inflammatory agents and antioxidants are also being explored as potential therapeutic options [44].

In conclusion, the management of neonatal RDS requires a multifaceted approach involving respiratory support, surfactant therapy, antenatal steroids, supportive care, and emerging therapies. Advances in non-invasive ventilation techniques, surfactant administration methods, and imaging technologies continue to improve outcomes for affected infants [45]. Collaborative efforts between neonatologists, nurses, respiratory therapists, and other healthcare professionals are essential to optimize care for neonates with RDS and reduce long-term complications [46].

References

1. Hermansen CL, Lorah KN. Respiratory distress in the newborn. Am Fam Physician. 2007;76(7):987-994.
2. Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome – 2019 update. Neonatology. 2019;115(4):432-450.
3. Polin RA, Carlo WA, Committee on Fetus and Newborn. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014;133(1):156-163.
4. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev. 1998;53(1):81-94.
5. Guglani L, Lakshminrusimha S, Ryan RM. Transient tachypnea of the newborn. Pediatr Rev. 2008;29(11):e59-e65.
6. Wiswell TE. Handling the meconium-stained infant. Semin Neonatol. 2001;6(3):225-231.

7. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770-1780.
8. Steinhorn RH. Diagnosis and treatment of pulmonary hypertension in infants and children. Pediatr Crit Care Med. 2010;11(2 Suppl):S79-S84.
9. Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anesth Analg. 1953;32(4):260-267.
10. Fanaroff AA, Martin RJ, Fanaroff JM. Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015.
11. Silverman WA, Anderson DH. A controlled clinical trial of effects of water mist on obstructive respiratory signs, death rate, and necropsy findings among premature infants. Pediatrics. 1956;17(1):1-10.
12. Diblasi RM. Nasal continuous positive airway pressure (CPAP) for the respiratory care of the newborn infant. Respir Care. 2009;54(9):1209-1235.
13. Raimondi F, Yousef N, Migliaro F, et al. Point-of-care lung ultrasound in neonatology: classification into descriptive and functional applications. Pediatr Res. 2021;90(3):524-531.
14. Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants. Neonatology. 2019;115(4):432-450.
15. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm infant. Early Hum Dev. 1998;53(1):81-94.
16. Schmölzer GM, Kumar M, Pichler G, et al. Non-invasive ventilation in neonates: a review of current evidence. Arch Dis Child Fetal Neonatal Ed. 2013;98(6):F384-F389.
17. Dargaville PA, Tingay DG, Morley CJ. An update on non-invasive ventilation in preterm infants. Early Hum Dev. 2016;102:1-8.
18. Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008;358(7):700-708.
19. Soll RF. Prophylactic versus rescue surfactant in preterm infants. Neonatology. 2020;117(3):303-309.
20. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2012;(11):CD001456.
21. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation versus selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007;(4):CD003063.
22. Gopel W, Kribs A, Ziegler A, et al. Less invasive surfactant administration in preterm infants. Neonatology. 2011;100(4):295-301.
23. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;(3):CD004454.
24. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515-525.
25. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for women at risk of preterm birth: a network meta-analysis. Cochrane Database Syst Rev. 2020;12:CD013645.
26. SUPPORT trial group. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970-1979.
27. Ho JJ, Subramaniam P, Davis PG. Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants. Cochrane Database Syst Rev. 2020;10:CD002271.
28. Dargaville PA, Aiyappan A, Cornelius A. Respiratory management of the preterm infant: current practice and emerging evidence. Lancet Respir Med. 2021;9(8):906-922.
29. Tapia JL, Bancalari A, Gonzalez A. Pulmonary outcomes in neonates with respiratory distress. Pediatr Pulmonol. 2017;52(5):635-642.
30. Reuter S, Moser C, Baack M. Respiratory distress in the newborn. Pediatr Rev. 2014;35(10):417-428.
31. Higgins RD, et al. Bronchopulmonary dysplasia: Pathogenesis and management. Am J Respir Crit Care Med. 2018;197(9):1078-1095.
32. Manley BJ, Owen LS, Doyle LW, et al. High-flow nasal cannulae in neonates. N Engl J Med. 2013;369(21):2104-2113.
33. Askie LM, et al. Oxygen saturation targets in preterm infants. N Engl J Med. 2018;378(17):1645-1657.
34. Zivanovic S, et al. Neonatal ventilation strategies. Lancet Respir Med. 2019;7(1):76-86.
35. Zysman-Colman Z, et al. Neonatal oxygen therapy: A review. Pediatrics. 2019;143(1):e20182837.
36. Shah PS. Late respiratory outcomes in preterm infants. Neonatology. 2017;111(4):342-348.

37. Bancalari E, Jain D. Bronchopulmonary dysplasia: Historical perspective. Semin Fetal Neonatal Med. 2019;24(4):207-211.
38. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. BMC Pediatr. 2019;19(1):220.
39. Doyle LW, et al. Corticosteroids and BPD. Pediatrics. 2017;140(5):e20171621.
40. Singh Y, et al. Neonatal lung ultrasound. J Perinatol. 2020;40(5):748-759.
41. Bhat R, et al. MRI in neonatal respiratory disease. Pediatr Radiol. 2019;49(4):469-482.
42. Chang YS, et al. Stem cell therapy in neonatal lung disease. Cell Transplant. 2019;28(5):463-472.
43. van Haaften T, et al. Stem cell therapies in neonatal lung injury. Am J Physiol Lung Cell Mol Physiol. 2019;317(5):L665-L678.
44. Ambalavanan N, et al. Anti-inflammatory therapies for neonatal lung disease. Semin Perinatol. 2020;44(8):151234.
45. Wright CJ, et al. Future therapies for neonatal RDS. Pediatr Pulmonol. 2020;55(3):611-624.
46. Eichenwald EC, et al. Management of neonatal respiratory distress. J Pediatr. 2021;234:10-20.